LURBINECTEDIN . En ASCO 2024 Serán 6 los POSTERS Que se Presentarán ... y Ninguna Presentación Oral ... Y Nada Sobre LAGOON NI IMFORTE .

 

Históricamente a PHARMAMAR Siempre le Han Ido Como un Tiro los Ensayos de FASE I y Los Ensayos de FASE II ... Otra Tema Ya Son los Ensayos de FASE III . 

El Póster Más Destacado Seran los Resultados de FASE I - II de LURBINECTEDIN Combinado Con IRINOTECAN :

*.- A phase II study of lurbinectedin with or without avelumab in small cell carcinoma of the bladder (LASER).

*.- Lurbinectedin versus platinum rechallenge in relapsed extensive stage small cell lung cancer : A retrospective cohort study.

*.- Efficacy and safety of lurbinectedin (LUR) with irinotecan (IRI) in a phase 2 expansion cohort of patients (Pts) with synovial sarcoma (SS).

*.- Randomized controlled, open-label, phase IIb/III study of lurbinectedin in combination with doxorubicin versus doxorubicin alone as first-line treatment in patients with metastatic leiomyosarcoma.

*.- Real-world safety and healthcare resource utilization (HCRU) of lurbinectedin (lurbi) in patients (pts) with small cell lung cancer (SCLC): Jazz EMERGE 402 updated analysis.